- Home
- NKTR vs SCD Comparison
NKTR vs SCD Comparison
Compare NKTR & SCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKTR
- SCD
- Stock Information
- Founded
- NKTR 1990
- SCD 2003
- Country
- NKTR United States
- SCD United States
- Employees
- NKTR N/A
- SCD N/A
- Industry
- NKTR Biotechnology: Pharmaceutical Preparations
- SCD Trusts Except Educational Religious and Charitable
- Sector
- NKTR Health Care
- SCD Finance
- Exchange
- NKTR Nasdaq
- SCD Nasdaq
- Market Cap
- NKTR 247.9M
- SCD N/A
- IPO Year
- NKTR 1994
- SCD N/A
- Fundamental
- Price
- NKTR $0.93
- SCD $16.71
- Analyst Decision
- NKTR Buy
- SCD
- Analyst Count
- NKTR 3
- SCD 0
- Target Price
- NKTR $4.00
- SCD N/A
- AVG Volume (30 Days)
- NKTR 2.2M
- SCD 62.6K
- Earning Date
- NKTR 11-07-2024
- SCD 01-01-0001
- Dividend Yield
- NKTR N/A
- SCD 9.63%
- EPS Growth
- NKTR N/A
- SCD N/A
- EPS
- NKTR N/A
- SCD N/A
- Revenue
- NKTR $93,137,000.00
- SCD N/A
- Revenue This Year
- NKTR $12.85
- SCD N/A
- Revenue Next Year
- NKTR N/A
- SCD N/A
- P/E Ratio
- NKTR N/A
- SCD N/A
- Revenue Growth
- NKTR 5.53
- SCD N/A
- 52 Week Low
- NKTR $0.47
- SCD $11.33
- 52 Week High
- NKTR $1.93
- SCD $15.87
- Technical
- Relative Strength Index (RSI)
- NKTR 33.04
- SCD 36.96
- Support Level
- NKTR $0.89
- SCD $17.45
- Resistance Level
- NKTR $1.04
- SCD $17.79
- Average True Range (ATR)
- NKTR 0.07
- SCD 0.37
- MACD
- NKTR -0.00
- SCD -0.14
- Stochastic Oscillator
- NKTR 14.81
- SCD 20.65
About NKTR Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.